JPRN-UMIN000018344
Completed
未知
Evaluation of Preventive Effect of tofogliflozin on cardiovascular function in type 2 diabetes with cardiovascular diseases - tofogliflozin study
tofogliflozin study group0 sites30 target enrollmentSeptember 1, 2015
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- type 2 diabetes with cardiovascular disease
- Sponsor
- tofogliflozin study group
- Enrollment
- 30
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) BMI \< 18\.0 2\) history of cerebral infarction 3\) patients whose dose of diuretics are changed within 3 months 4\) estimated GFR \< 45 ml/min 5\) patients inplanted pacemaker 6\) patients with pregnancy and lactation 7\) patiets enrolled other clinical trial
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Comparison of safety and efficacy of Tofogliflozin and Ipragliflozin in patients with type 2 diabetestype 2 diabetesJPRN-UMIN000037158Minami Osaka hospital24
Recruiting
Phase 4
Effect of tofogliflozin on pancreatic beta-cell functioType 2 diabetesJPRN-jRCTs011230006akamura Akinobu70
Completed
Not Applicable
Effects of tofogliflozin treatment on suppression of nocturia and promotion of urinary sodium excretion.JPRN-UMIN000048030Department of Metabolism and Endocrinology, Akita University Graduate School of Medicine36
Unknown
Phase 2
Clinical Pharmacology Study of Tofogliflozin --Evaluation of influence by degree of kidney functionType 2 diabetesJPRN-jRCT2080221532Chugai Pharmaceutical Co., Ltd.40
Unknown
Phase 1
Drug-drug interaction study (2) of TofoglifloziJPRN-jRCT2080221710Chugai Pharmaceutical Co., Ltd.87